Akero Therapeutics, Inc.

AKRO

Explore Our Financial Data > Companies > Akero Therapeutics, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	AKRO
CIK	0001744659
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080
Website	akerotx.com
Phone	650-487-6488
CEO	Andrew Cheng
Employees	30

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-292.82 million
Net Income	$-292.82 million
Net Income to Common	$-293.10 million
EPS	$-3.74

View All

Balance Sheet

Cash	$176.03 million
Assets	$1.01 billion
Liabilities	$47.94 million
Common Equity	$957.64 million
Liabilities & Equity	$1.01 billion

View All

Cash Flow Statement

Net Income	$-292.82 million
Cash From Operating Activities	$-250.17 million
Cash From Investing Activities	$-330.79 million
Cash From Financing Activities	$440.93 million
Change in Cash	$-140.03 million

View All

Calculations

NOPAT	$-231.01 million
EBITDA	$-340.05 million
Price to Earnings	N/A
Price to Book	$4.70
ROE	-34.53%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Novo Nordisk has completed its acquisition of Akero Therapeutics

Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in cash (or aggregated value of 4.7 billion USD) and a non-transferable Contingent Value Right

Article Link

Liver Fibrosis Research Report 2025-2035: Market Driven by Innovation from Akero, Sagimet, Inventiva, Novo Nordisk, Viking, Boston Pharma, Aligos, Boehringer Ingelheim, and 89bio

Liver fibrosis is a growing global concern, driven by chronic conditions like hepatitis, obesity, and alcohol use. This progressive liver disease, marked by scar tissue buildup, can advance to cirrhosis or liver cancer if untreated. Advances in antifibrotic therapies and non-invasive diagnostics are enhancing disease management, while liver transplantation remains a definitive cure. As liver fibrosis prevalence rises, so does the demand for treatment, spurring market growth. Challenges include l

Article Link

Akero Therapeutics (AKRO): Examining Valuation After Strong Year-to-Date Share Price Gains

Akero Therapeutics (AKRO) is catching the market’s eye after shares moved slightly higher this week, following a recent stretch of strong year-to-date gains. Investors are now keeping an eye on what might come next for the biotech name. See our latest analysis for Akero Therapeutics. After an outstanding run so far this year, Akero Therapeutics has continued to capture investor attention, with momentum remaining strong. The share price jumped over 92% year-to-date and its one-year total...

Article Link

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH Digital pathology reinforces fibrosis improvements observed through conventional pathology in the 96-week Phase 2b HARMONY trial SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company develop

Article Link

Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments.

Contingent value rights have become common in biotechnology deals. More than half of all transactions this year include them, according to a Jefferies report in October.

Article Link